“…One of the major problems associated with 5-FU therapy is the development of resistance to the drug. Resistance to 5-FU may occur by a number of mechanisms, including alterations in the enzymes implicated in the metabolism or in the mechanism of action of the drug, especially in the target enzyme (for review, see Peters et al, 2002), also, alterations in molecules such as p53 (Lowe et al, 1993;Bunz et al, 1999;Longley et al, 2002;Tominaga et al, 2010) and in proteins critical in the response to DNA damage, such as ataxia telangiectasia mutated (ATM) or ataxia telangiectasia and Rad3 related (ATR) (for review, see Wyatt and Wilson III, 2009). For example, ATR has been shown to be an essential mediator in the antitumoral properties of 5-FU (Wilsker and Bunz 2007) through the control exerted on the mismatch repair system (Liu et al, 2008) or on CHK1, a regulatory component of the DNA damage checkpoint (Jardim et al, 2009).…”